Immune cell therapy shows promise for tough ovarian cancer

NCT ID NCT06321484

First seen Mar 14, 2026 · Last updated Apr 24, 2026 · Updated 5 times

Summary

This early-stage study tests a new treatment called CIML NK cell therapy for people with recurrent ovarian cancer that no longer responds to platinum chemotherapy. The therapy uses specially trained natural killer cells from a donor to attack the cancer. The study aims to find the safest dose and see if it can shrink tumors. About 18 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.